Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Single-cell analysis of human MAIT cell transcriptional, functional and clonal diversity

Garner LC. et al, (2023), Nature Immunology

A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75

Huo J. et al, (2023), Cell Reports, 42, 111903 - 111903

Impaired humoral and cellular response to primary COVID ‐19 vaccination in patients less than 2 years after allogeneic bone marrow transplant

Murray SM. et al, (2022), British Journal of Haematology, 198, 668 - 679

Comparison of two T-cell assays to evaluate T-cell responses to SARS-CoV-2 following vaccination in naïve and convalescent healthcare workers

Phillips E. et al, (2022), Clinical and Experimental Immunology, 209, 90 - 98

Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum

Tuekprakhon A. et al, (2022), Cell, 185, 2422 - 2433.e13

Potent cross-reactive antibodies following Omicron breakthrough in vaccinees

Nutalai R. et al, (2022), Cell, 185, 2116 - 2131.e18

Adenovirus vectors activate Vδ2 + γδT cells in a type I interferon‐, TNF‐, and IL‐18‐dependent manner

Provine NM. et al, (2022), European Journal of Immunology, 52, 835 - 837

Human MAIT cells show clonal diversity but transcriptional and functional homogeneity

Garner LC. et al, (2022)

Comparison of two T cell assays to evaluate T cell responses to SARS-CoV-2 following vaccination in naïve and convalescent healthcare workers

Phillips E. et al, (2022)

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

Dejnirattisai W. et al, (2022), Cell, 185, 467 - 484.e15

T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study

Angyal A. et al, (2022), The Lancet Microbe, 3, e21 - e31

Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

Dejnirattisai W. et al, (2021)

T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses

Ogbe A. et al, (2021), Nature Communications, 12

Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine.

Payne RP. et al, (2021), Cell, 184, 5699 - 5714.e11

Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine

Payne RP. et al, (2021), Cell, 184, 5699 - 5714.e11

Identification of immune correlates of fatal outcomes in critically ill COVID-19 patients

Youngs J. et al, (2021), PLOS Pathogens, 17, e1009804 - e1009804

Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern.

Skelly DT. et al, (2021), Nature communications, 12

Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern

Skelly DT. et al, (2021), Nature Communications, 12

The Duration, Dynamics, and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Responses in Individual Healthcare Workers

Lumley SF. et al, (2021), Clinical Infectious Diseases, 73, e699 - e709

Sustained T Cell Immunity, Protection and Boosting Using Extended Dosing Intervals of BNT162b2 mRNA Vaccine

Payne RP. et al, (2021), SSRN Electronic Journal

Load More

Include forthcoming?